Page last updated: 2024-10-26

edrophonium and Diabetic Angiopathies

edrophonium has been researched along with Diabetic Angiopathies in 1 studies

Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.

Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Matthews, DM1
Martyn, CN1
Riemersma, RA1
Clarke, BF1
Ewing, DJ1

Other Studies

1 other study available for edrophonium and Diabetic Angiopathies

ArticleYear
Noradrenaline response to edrophonium (Tensilon) and its relation to other autonomic tests in diabetic subjects.
    Diabetes research (Edinburgh, Scotland), 1987, Volume: 6, Issue:4

    Topics: Autonomic Nervous System Diseases; Blood Pressure; Circadian Rhythm; Diabetes Mellitus, Type 1; Diab

1987